[11-02-22] – Inclusion of Zoledronic acid (4mg/5mL concentrated solution for IV Infusion) for individuals with Malignancy-Related Bone Disease as per DC No. 2022-0560 { p.49}

[10-18-22] – Inclusion of Insulin Glargine 100 IU/mL, 10 mL Vial and 100 IU/mL, 3 mL Pre-filled Pen as per DC No. 2022-0537 { p.26}

[09-29-22] – Addtional formulation for Potassium (as citrate): 1620 mg (15 mEq) extended release (ER) tablet) as per DC No. 2022-0291 and additional clarification as per DC No. 2022-0291-A { p.40}

[08-03-22] – Change in the Generic Name of Nicotine Polacrilex Medicated Chewing Gum to Nicotine as per DC No. 2022-0400  { p.36}

[06-02-22] – Inclusion of Tocilizumab as per DC No. 2022-0289 : 80 mg/4 mL (20 mg/mL) Concentrate Solution for IV Infusion ; 200 mg/10 mL (20 mg/mL) Concentrate Solution for IV Infusion ; 400 mg/20 mL (20 mg/mL) Concentrate Solution for IV Infusion { p.47}

[01-21-22] – Re-inclusion of Vasopressin as per DC No. 2022-0164 : 20 IU/mL (IM/IV) { p.48}

[01-21-22] – Inclusion of Emtricitabine 200 mg FDC + Tenofovir Disoproxil Fumarate 300 mg fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP) as per DC No. 2022-0044 : 250 mg tablet { p.16}

[01-21-22] – Additional formulation for Sambong as per DC No. 2022-0015 : 250 mg tablet { p.43}

[09-27-21] – Inclusion of two-dose Inactivated Polio Vaccine as per DC No. 2021-0410: 0.5 mL per dose (suspension for injection) in 5 mL multidose vial (IM/SC) { p.25}

[09-27-21] – Inclusion of Tenofovir +Lamivudine + Dolutegravir as per DC No. 2021-0400: 300 mg + 300 mg + 50 mg (fixed-dose combination) tablet { p.45}

[09-27-21] – Inclusion of Dolutegravir as per DC No. 2021-0423: 50 mg tablet { p.15}

[04-07-21] – Additional volume for Sodium Hyaluronate as per DM No. 2021-0158 : 0.1% (1 mg/mL), 15 mL bottle { p.41}

[04-07-21] – Additional formulation for Peritoneal Dialysis Solution as per DM No. 2021-0158 : Sterile with 2.5% dextrose, 2 L and 5 L bottle/bag { p.36}

[07-23-20] – Additional pediatric formulation for Lopinavir + Ritonavir as per DM No. 2020-0310 : 40 mg + 10 mg oral pellets contained in capsule { p.29}

[07-23-20] – Additional pediatric formulation for Nevirapine as per DM No. 2020-0310 : 50 mg dispersible tablet { p.33}

[07-23-20] – Additional pediatric formulation for Lamuvidine + Zidovudine as per DM No. 2020-0310 : 30 mg + 60 mg dispersible table{ p.27}

[07-03-20] – Revised formulation for Ipratropium + Salbutamol as per DM No. 2020-0321 : { p.25}

[01-27-20] – Added Pantoprazole as per DM No. 2020-0018 : { p.36}